News | Cardio-oncology | January 03, 2019

Breast Cancer Patients Have Less Heart Damage With Heart Drug and Trastuzumab

Study finds heart drug carvedilol reduces major cardiac side effects of breast cancer treatment

Breast Cancer Patients Have Less Heart Damage With Heart Drug and Trastuzumab

January 3, 2019 — Breast cancer patients who take a heart drug at the same time as trastuzumab have less heart damage, according to a study presented recently at EuroEcho-Imaging 2018, Dec. 5-8 in Milan, Italy.1

“Heart damage is a major side effect of the breast cancer drug trastuzumab and may force patients to stop treatment,” said lead author Maryam Moshkani Farahani, M.D., associate professor, Baqiyatallah University of Medical Sciences, Tehran, Iran. “Our study suggests that patients who take the beta-blocker carvedilol together with trastuzumab have less heart damage than those who take trastuzumab alone.”

The study enrolled 71 patients with non-metastatic HER2-positive breast cancer. Patients were randomly allocated to receive trastuzumab with, or without, carvedilol.

Impaired function of the heart’s left ventricle is the main type of heart damage caused by trastuzumab. Carvedilol is used to treat patients with impaired left ventricular function after a heart attack. It is also prescribed for heart failure and high blood pressure.

For the study, an imaging technique called two-dimensional speckle tracking echocardiography was used to assess the systolic and diastolic function of the left ventricle initially and at three months. Specifically, systolic function was measured using global longitudinal strain and strain rate, while diastolic function was assessed with strain rate.

According to all of the measurements, systolic and diastolic left ventricular function were better preserved at three months in patients who took carvedilol with trastuzumab compared to those who took trastuzumab alone.

The pumping function of the heart (left ventricular ejection fraction) did not differ between treatment groups at the start of the study or at three months. “The measures we used to assess left ventricular function – namely global longitudinal strain and strain rate – are more sensitive than left ventricular ejection fraction,” explained Moshkani Farahani.

She noted that carvedilol can cause side effects, such as dizziness, drowsiness, fainting, mood changes, shortness of breath and diarrhoea. Patients who feel unwell when taking the medication should consult their doctor.

Moshkani Farahani concluded: “The findings indicate that carvedilol may be an effective way to prevent the heart damage caused by trastuzumab treatment. We now advise our patients with non-metastatic HER2-positive breast cancer to take prophylactic carvedilol, but a larger study is needed before firm recommendations can be made.”

For more information: www.escardio.org

 

Reference

1. Moshkani Farahani M., Nourian S. Assessment of treatment with Carvedilol in preventing early stage left ventricular dysfunction in breast cancer patients by 2D speckle tracking echocardiography. Presented at EuroEcho-Imaging, Dec. 5, 2018.

Related Content

News | Cardiac Imaging

November 10, 2021 — Philips, a global leader in health technology, announced that it has signed an agreement to acquire ...

Home November 10, 2021
Home
News | Cardiac Imaging

November 1, 2021 — According to ARRS’ American Journal of Roentgenology (AJR), radiologists need to be cognizant of the ...

Home November 01, 2021
Home
Feature | Cardiac Imaging

October 6, 2021 – A new study published in Radiology: Cardiothoracic Imaging on cardiac imaging trends over a decade ...

Home October 06, 2021
Home
News | Cardiac Imaging

September 22, 2021 — Test selection should be a shared decision between patient and physician rather than directed by ...

Home September 22, 2021
Home
Feature | Cardiac Imaging | By Dave Fornell, Editor

In the past several years, a few cardiac ultrasound vendors have developed new ways to image the intricate flow of ...

Home August 17, 2021
Home
News | Cardiac Imaging

June 15, 2021 — A cardiac MRI of athletes who had COVID-19 is seven times more effective in detecting inflammation of ...

Home June 15, 2021
Home
News | Cardiac Imaging

June 14, 2021 — Heart disease and cancer are the leading causes of death in the United States, and it’s increasingly ...

Home June 14, 2021
Home
News | Cardiac Imaging

May 12, 2021 — According to the British Heart Foundation, heart and circulatory diseases cause more than a quarter (27 ...

Home May 12, 2021
Home
News | Cardiac Imaging

March 31, 2021 — ScImage Inc. celebrates its cloud partnership with Digirad Health after a year of successful deployment ...

Home March 31, 2021
Home
News | Cardiac Imaging

November 17, 2020 — Diagnostic imaging techniques were able to find the underlying cause of heart attack in many women ...

Home November 17, 2020
Home
Subscribe Now